CTOs on the Move

Ellipse Technologies

www.ellipse-tech.com

 
Ellipse Technologies is a privately held medical device company that is dedicated to the design, development and successful commercialization of non-invasively adjustable, remote controlled implants for a broad spectrum of spinal and orthopedic applications. As part of its product portfolio, the company has developed remote controlled distraction systems using magnets which may eliminate the need for additional surgeries for adjustment. The initial revolutionary products restore proper anatomic position and alignment of the spine and correct limb length discrepancies of the femur and tibia. Ellipse is located in Irvine, California.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Ellipse Technologies raised $10M on 06/29/2015

Similar Companies

Grabber Performance Group

Grabber Performance Group is a Wyoming, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agno Pharma

Agno Pharma is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omega Medical Products Corp

Omega Medical Products Corp is a Yonkers, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.

Telligen

Telligen is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Des Moines, IA. To find more information about Telligen, please visit www.telligen.org